BACKGROUND: Narcolepsy is a lifelong, rare neurological sleep disorder characterized by chronic, excessive attacks of daytime sleepiness. This disease is often extremely incapacitating, interfering with every aspect of life, in work and social settings. OBJECTIVE: The purpose of this study is to specify the treatment costs of patients in Central Europe (Czech Republic), while the attention is mainly paid to the drugs that were fully or partially covered by public health insurance. Furthermore, concomitant therapy is also evaluated, since it incurs a certain financial burden for patients and their family members. On the basis of the calculated costs, impact on the public budget is evaluated. PATIENTS AND METHODS: This study monitors the direct costs of the drugs for 13 patients, who represent ~1.3% of the total number of diagnosed patients in the Czech Republic, and evaluates the costs associated with their treatment during the period from January 9, 2011 to April 23, 2013. RESULTS: Most of the treatment costs (~80%) were covered by publicly available sources. This finding is also true for the concomitant therapy of comorbidities. Additional payments for the drugs constitute about 20% of the total costs.

Biomedical Research Center University Hospital Hradec Králové; Faculty of Informatics and Management University of Hradec Králové Hradec Králové Czech Republic

Department of Applied Linguistics Faculty of Informatics and Management

Department of Chemistry Faculty of Science University of Hradec Králové; Biomedical Research Center University Hospital Hradec Králové

Department of Economics Faculty of Informatics and Management

Zobrazit více v PubMed

Tucci V, Plazzi G. Cataplexy: an affair of pleasure or an unpleasant affair? Neurosci Lett. 2009;450(2):90–91. PubMed

Billiard M, Bassetti C, Dauvilliers Y, et al. EFNS Task Force EFNS guidelines on management of narcolepsy. Eur J Neurol. 2006;13(10):1035–1048. PubMed

Rocca FL, Finotti E, Pizza F, et al. Psychosocial profile and quality of life in children with Type 1 > narcolepsy: a case-control study. Sleep. 2016;39(7):1389–1398. PubMed PMC

Meletti S, Vaudano AE, Pizza F, et al. The brain correlates of laugh and cataplexy in childhood narcolepsy. J Neurosci. 2015;35(33):11583–11594. PubMed PMC

Han F, Lin L, Schormair B, et al. HLA DQB1*06:02 negative narcolepsy with hypocretin/orexin deficiency. Sleep. 2014;37(10):1601–1608. PubMed PMC

Partinen M, Kornum BR, Plazzi G, Jennum P, Julkunen I, Vaarala O. Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet Neurol. 2014;13(6):600–613. PubMed

Khatami R, Luca G, Baumann CR, et al. European Narcolepsy Network The European Narcolepsy Network (EU-NN) database. J Sleep Res. 2016;25(3):356–364. PubMed

Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 2007;369(9560):499–511. PubMed

U.S. Xyrem Multicenter Study Group A randomized, double-blind, placebo-controlled, multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo in the treatment of narcolepsy. Sleep. 2002;25(1):42–49. PubMed

U.S. Xyrem Multicenter Study Group Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med. 2004;5(2):119–123. PubMed

Xyrem International Study Group Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med. 2005;6(5):415–421. PubMed

Federation of Neurescience Societies 2016. [Accessed September 24, 2016]. Available from: http://www.fens.org/

Mohelska H, Maresova P, Valis M, Kuca K. Alzheimer’s disease and its treatment costs: case study in the Czech Republic. Neuropsychiatr Dis Treat. 2015;11:2349–2354. PubMed PMC

Marešová P, Mohelská H, Dolejš J, Kuča K. Socio-economic aspects of Alzheimer’s disease. Curr Alzheimer Res. 2015;12(9):903–911. PubMed

Marešová P, Klímová B, Kuča K. Alzheimer’s disease: cost cuts call for novel drugs development and national strategy. Ceska Slov Farm. 2015;64(1–2):25–30. PubMed

Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programs. 2nd ed. New York, NY: Oxford University Press; 1997.

Lhotáková M, Kubáčková K. European initiative in the field of rare diseases. Current Europe. 2013;12:19–37.

SUKL Drug pricing. 2015. [Accessed October 15, 2015]. Available from: http://www.sukl.cz/